IMO-2125 – An Investigational Intratumoral Toll-Like Receptor 9 Agonist Modulates the Tumor Microenvironment

(Presentation, Idera Pharmaceuticals, NOV 9, 2016, View Source [SID1234516451])

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!